Edition:
India

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

14.77USD
1:30am IST
Change (% chg)

$0.06 (+0.41%)
Prev Close
$14.71
Open
$14.65
Day's High
$14.96
Day's Low
$14.58
Volume
176,547
Avg. Vol
118,634
52-wk High
$17.95
52-wk Low
$7.54

Chart for

About

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor... (more)

Overall

Beta: 4.16
Market Cap(Mil.): $551.05
Shares Outstanding(Mil.): 47.14
Dividend: --
Yield (%): --

Financials

BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA

* KARYOPHARM'S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

10 Apr 2018

BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80

* KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

15 Mar 2018

Biogen forecasts robust 2018, quarterly revenue beats on Spinraza sales

U.S. drugmaker Biogen Inc on Thursday reported fourth-quarter revenue that beat Wall Street estimates on higher sales for its drug Spinraza and forecast an upbeat 2018, sending its shares up 3 percent in premarket trading.

25 Jan 2018

BRIEF-Karyopharm Announces Agreement For Biogen To Acquire KPT-350

* KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS

25 Jan 2018

BRIEF-Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock

* KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION

02 Dec 2017

BRIEF-Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​

* Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​ Source text: (http://bit.ly/2h9XeaC) Further company coverage:

07 Nov 2017

BRIEF-Karyopharm Q3 loss per share $0.65

* Karyopharm reports third quarter 2017 financial results and highlights recent progress

02 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.53 +0.04
Roche Holding Ltd. (ROG.S) CHF216.50 -0.05
Roche Holding Ltd. (RO.S) CHF220.20 -0.80
AstraZeneca plc (AZN.L) 4,955.50 -9.00

Earnings vs. Estimates